Rainer Blair, Danaher CEO (Photo by Lintao Zhang/Getty Images)
October 25, 2023 07:20 AM EDT
China
Outsourcing
Pharma

Dana­her’s third-quar­ter rev­enue from biotech ser­vices down 19% amid slow­down in Chi­na, US

Ayisha Sharma

News Reporter

An an­tic­i­pat­ed re­duc­tion in biotech sales con­tributed to Dana­her’s third-quar­ter per­for­mance drop­ping rel­a­tive to last year, the com­pa­ny re­vealed Tues­day. This is in the midst …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times